NicOx SA

278 articles about NicOx SA

• NicOx SA Receives World Health Organization Acceptance Of Naproxcinod As Generic Name For HCT 3012, First In A New Class Of Treatments For Osteoarthritis

  6/19/2006

• NicOx SA Announces Euro 15 Million Equity Investment By Pfizer Inc.

  6/2/2006

• NicOx SA Partner Topigen Pharmaceuticals Inc. Initiates Phase 2 Program For TPI-1020 In Respiratory Disorders

  5/24/2006

• NicOx SA Completes Enrolment Of Phase 3 Trial For HCT 3012 In Osteoarthritis Ahead Of Schedule

  5/24/2006

• NicOx SA And Grupo Ferrer Internacional S.A. Select Candidate For Development In Dermatology Collaboration

  5/16/2006

• NicOx SA Initiates New Trial To Establish HCT 3012 As Osteoarthritis Treatment With Beneficial Blood Pressure Profile

  5/4/2006

• NicOx SA Announces Fund Raising Of € 45.5 Million By Private Placement

  4/28/2006

• NicOx SA And Merck & Co., Inc. Sign Major Exclusive Worldwide Agreement In Antihypertensive Field; Worth Up To $340.2 Million

  3/21/2006

• NicOx SA Soars On $385 Million Eye Drug Deal With Pfizer Inc.

  3/2/2006

• NicOx SA Compound Demonstrates Excellent Preclinical Results In Pfizer Inc. Glaucoma Collaboration

  3/2/2006

• NicOx SA 2005 Financial Results: Strong Revenue Growth And Solid Progress With Clinical Programs And Partnerships

  3/1/2006

• NicOx SA Announces Initiation Of Phase 3 Trial For HCT 3012 In Osteoarthritis

  12/20/2005

• NicOx SA Announces Pfizer Inc.'s Exercise Of Option To Develop Lead Compound From Ophthalmology Collaboration

  11/22/2005

• NicOx SA Appoints PRA International, Inc. - Phase 3 Program For HCT 3012 To Be Initiated

  11/17/2005

• NicOx SA Announces Results Of A Phase 2 Trial For NCX 4016 In PAOD

  11/16/2005

• Merck & Co., Inc. And NicOx SA Extend Research Collaboration

  11/2/2005

• NicOx SA And TOPIGEN Pharmaceuticals Inc. Sign Deal On Respiratory Drug

  10/27/2005

• NicOx Forms $37M Agreement With Pfizer In Undisclosed Area

  9/1/2004